RPL37A and breast carcinoma: Interestingly, among genes affecting drug response prediction, CPM was found to contribute to chemoresistance in GC49, whereas RPL37A was a potential biomarker for response to neoadjuvant chemotherapy (NCT) against non-metastatic locally advanced breast carcinoma (LABC)41.